About eloxx pharmaceuticals - ELOX
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.
ELOX At a Glance
Eloxx Pharmaceuticals, Inc.
480 Arsenal Way
Watertown, Massachusetts 02451
| Phone | 1-781-577-5300 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -36,065,000.00 | |
| Sector | Health Technology | Employees | 18 | |
| Fiscal Year-end | 12 / 2023 | |||
| View SEC Filings |
ELOX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.063 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -6.25 |
ELOX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,003,611.111 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ELOX Liquidity
| Current Ratio | 0.872 |
| Quick Ratio | 0.872 |
| Cash Ratio | 0.843 |
ELOX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -108.856 |
| Return on Equity | -615.234 |
| Return on Total Capital | -1,323.972 |
| Return on Invested Capital | -217.154 |
ELOX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 491.336 |
| Total Debt to Total Assets | 63.362 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 319.09 |